These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10868894)

  • 1. Cotherapy with recombinant human IGF-I and insulin improves glycemic control in type 1 diabetes.
    Lanzetta P; Malara C
    Diabetes Care; 2000 Mar; 23(3):436-7. PubMed ID: 10868894
    [No Abstract]   [Full Text] [Related]  

  • 2. Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM Study Group.
    Thrailkill KM; Quattrin T; Baker L; Kuntze JE; Compton PG; Martha PM
    Diabetes Care; 1999 Apr; 22(4):585-92. PubMed ID: 10189536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does IGF-I therapy in insulin-dependent diabetes mellitus limit complications?
    Møller N; Orskov H
    Lancet; 1997 Oct; 350(9086):1188-9. PubMed ID: 9652553
    [No Abstract]   [Full Text] [Related]  

  • 4. Insulin-like growth factor type 1--friend or foe?
    Knott RM
    Br J Ophthalmol; 1998 Jul; 82(7):719-20. PubMed ID: 9924357
    [No Abstract]   [Full Text] [Related]  

  • 5. Dual hormonal replacement with insulin and recombinant human insulin-like growth factor I in IDDM. Effects on glycemic control, IGF-I levels, and safety profile.
    Quattrin T; Thrailkill K; Baker L; Litton J; Dwigun K; Rearson M; Poppenheimer M; Giltinan D; Gesundheit N; Martha P
    Diabetes Care; 1997 Mar; 20(3):374-80. PubMed ID: 9051390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity.
    Clemmons DR; Moses AC; McKay MJ; Sommer A; Rosen DM; Ruckle J
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1518-24. PubMed ID: 10770191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system.
    Thrailkill K; Quattrin T; Baker L; Litton J; Dwigun K; Rearson M; Poppenheimer M; Kotlovker D; Giltinan D; Gesundheit N; Martha P
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1181-7. PubMed ID: 9100593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood glucose control and vision outcome in diabetes.
    Minckler D
    Ophthalmology; 1995 May; 102(5):703-4. PubMed ID: 7777267
    [No Abstract]   [Full Text] [Related]  

  • 9. Mecasermin (recombinant human insulin-like growth factor I).
    Rosenbloom AL
    Adv Ther; 2009 Jan; 26(1):40-54. PubMed ID: 19198769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does recombinant human insulin-like growth factor-1 have a role in the treatment of diabetes?
    Dunger DB; Acerini CL
    Diabet Med; 1997 Sep; 14(9):723-31. PubMed ID: 9300221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of insulin-like growth factor-I in the control of glucose homeostasis.
    Clemmons DR
    Curr Opin Pharmacol; 2006 Dec; 6(6):620-5. PubMed ID: 17030015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does recombinant human insulin-like growth factor I have a role in the treatment of type I (insulin dependent) diabetes during puberty?
    Dunger DB; Cheetham TD
    J Pediatr Endocrinol Metab; 1995; 8(4):237-42. PubMed ID: 8821899
    [No Abstract]   [Full Text] [Related]  

  • 13. The therapeutic potential of recombinant human insulin-like growth factor-I.
    Cotterill AM
    Clin Endocrinol (Oxf); 1992 Jul; 37(1):11-5. PubMed ID: 1424187
    [No Abstract]   [Full Text] [Related]  

  • 14. Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients.
    Jabri N; Schalch DS; Schwartz SL; Fischer JS; Kipnes MS; Radnik BJ; Turman NJ; Marcsisin VS; Guler HP
    Diabetes; 1994 Mar; 43(3):369-74. PubMed ID: 8314009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of insulin-dependent diabetes: hypoglycaemia and the eye.
    Frier BM
    Eye (Lond); 1993; 7 ( Pt 2)():293-7. PubMed ID: 7607349
    [No Abstract]   [Full Text] [Related]  

  • 16. Mixing insulin lispro and ultralente insulin.
    Bastyr EJ; Holcombe JH; Anderson JH; Clore JN
    Diabetes Care; 1997 Jun; 20(6):1047-8. PubMed ID: 9167130
    [No Abstract]   [Full Text] [Related]  

  • 17. High dose intravenous, but not low dose subcutaneous, insulin-like growth factor-I therapy induces sustained insulin sensitivity in severely resistant type I diabetes mellitus.
    Usala AL; Madigan T; Burguera B; Cefalu W; Sinha MK; Powell JG; Usala SJ
    J Clin Endocrinol Metab; 1994 Aug; 79(2):435-40. PubMed ID: 8045959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor-I for the treatment of type 1 diabetes.
    Acerini CL; Dunger DB
    Diabetes Obes Metab; 2000 Dec; 2(6):335-43. PubMed ID: 11225962
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes.
    Clemmons DR; Sleevi M; Allan G; Sommer A
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2652-8. PubMed ID: 17426090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of insulin on the insulin-like growth factor system in children with new-onset insulin-dependent diabetes mellitus.
    Bereket A; Lang CH; Blethen SL; Gelato MC; Fan J; Frost RA; Wilson TA
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1312-7. PubMed ID: 7536205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.